Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Semi Equipment Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Return to Sender who wrote (29341)	3/15/2006 7:23:00 AM
From: sixty2nds	Respond to of 95646

06:50 Early Research Calls II Upgrades: UBS upgrades PMC Sierra (PMCS 11.32) to Buy from Neutral. Donwgrades: Credit Suisse assumes coverage of FEI Co (FEIC 20.84) with an Underperform down from Neutral and lowers their tgt to $16 from $17.50 following their sector call... Credit assumes coverage of Novellus (NVLS 25.67) with a Neutral down from Outperform and lowers their tgt to $24 from $28 noting concerns on growth and ceiling on margin expansion... HSBC downgrades Anglo American (AAUK 17.65) to Neutral. Miscellaneous: Credit Suisse assumes coverage of the Semiconductor Equiptment sector with a Martket Weight from Underweight saying near term, their outlook for a Mid-Cycle pause in fundamentals offsets an improving long-term secular outlook. Specifically, they expect a bigger mid-year correction for semi-cap orders than what is factored into consensus expectations. Stocks they are transitioning coverage today: AMAT, KLAC (Restricted), NVLS, LRCX, ACLS, VSEA, CYMI, FEIC, and BRKS... Clear Asset Mgmt initiates Schnitzer Steel (SCHN 32.94) with Buy and a $38 tgt based on valuation... HSBC initiates Rio Tinto (RTP 188.09) and BHP Billiton (BHP 35.46) with Overweights saying commodity prices will stay higher for longer, macro signals do not signal a sell, and sector valuations are supportive... HSBC notes that Astrazeneca (AZN 50.92) had a positive Asteriod study, and they think consensus numbers of Crestor likely to move up.